Tag Archives: Medication effects – wanted and unwanted
True Risk of Serious Harms with Antidepressants Still Uncertain
True Risk of Serious Harms with Antidepressants Still Uncertain http://www.bmj.com/content/352/bmj.i65 Abstract Objective To study serious harms associated with selective serotonin and serotonin-norepinephrine reuptake inhibitors. Design Systematic review and meta-analysis. Main outcome measures Mortality and suicidality. Secondary outcomes were aggressive behaviour and akathisia. Data … Continue reading →
Quetiapine safety in older adults?
Quetiapine safety in older adults? Journal of Clinical Pharmacy and Therapeutics Volume 41, Issue 1, pages 7–18, February 2016 http://onlinelibrary.wiley.com/doi/10.1111/jcpt.12357/abstract Abstract WHAT IS KNOWN AND OBJECTIVE: Quetiapine is a second-generation antipsychotic that is commonly prescribed for a range of approved and off-label indications … Continue reading →
Severe parkinsonism due to Reglan (metoclopramide): the importance of early recognition.
A reminder.. The well-established but under-appreciated dopamine-blocking effect of metoclopramide. Ned Tijdschr Geneeskd. 2013;157(26):A6037. Severe parkinsonism due to Reglan (metoclopramide): the importance of early recognition. [Article in Dutch] de Ronde MW1, Kingma HJ, Munts AG. Author information 1Kennemer Gasthuis, afd. Neurologie, Haarlem, … Continue reading →
Risk of major cardiac malformations associated with paroxetine use during the first trimester of pregnancy
The risk of major cardiac malformations associated with paroxetine use during the first trimester of pregnancy: A systematic review and meta-analysis http://onlinelibrary.wiley.com/doi/10.1111/bcp.12849/abstract Anick Bérard1,2,*, Noha Iessa1,2, Sonia Chaabane1,2, Flory T. Muanda1,2, Takoua Boukhris1,2 and Jin-Ping Zhao1,2 DOI: 10.1111/bcp.12849 This article … Continue reading →
Meta-analyses with industry involvement are massively published and report no caveats for antidepressants.
CONCLUSION:
There is a massive production of meta-analyses of antidepressants for depression authored by or linked to the industry, and they almost never report any caveats about antidepressants in their abstracts. Our findings add a note of caution for meta-analyses with ties to the manufacturers of the assessed products. Continue reading →